Nurix Therapeutics
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1700 Owens St Ste 205, San Francisco, Ca...Phone Number
(415) 660-5320Website
www.nurixtx.comRevenue
$36.8 MillionStock Symbol
NRIXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Nurix Therapeutics
Nurix Therapeutics founded in 2009 and headquartered in San Francisco, California, develops therapies that control disease-causing proteins and develops drugs as treatments for hematologic cancers and immune-mediated diseases including immuno-oncology therapeutics for cancer.Explore more
Nurix Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nurix Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Nurix Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Nurix Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Nurix Therapeutics launches new products
Click to see if Nurix Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Nurix Therapeutics
Funding: Get notified immidiatlly once Nurix Therapeutics has new funding data
Check out if Nurix Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Nurix Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Nurix Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Nurix Therapeutics
Compare insights from companies similar to Nurix Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Nurix Therapeutics
$36.8M
201-500
Public
$354.1M
2009
CR
Christine RingChief Legal Officer and Chief Compliance Officer
Company Profile Activity
Activity Insights
Nurix Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nurix Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nurix Therapeutics.
Nurix Therapeutics financials insights
Gather financial insights about Nurix Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series B
$25.1M
2020
Other Financing Round
$120M
Stock Offering
$209M
Nurix Therapeutics Tech Stack
A closer look at the technologies used by Nurix Therapeutics
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Earnings
Earnings, Finance
Nurix Therapeutics News & Media
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitorNurix Closes Roche Collaboration After HSR Clearance For Bexobrutide, Secures $700 ...
Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, announced the closing of its previously announced global collaboration agreement with Roche Holding AG (RHHBY) to co-develop and co-commercialise Bexobrutideg, following expiration of the waiting period under the Hart-Cottrell-Rodino Antitrust Improvements Act of 1976.Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the closing of its previously announced global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nurix Therapeutics
Sign Up For FreeTo access detailed company insights
Nurix Therapeutics founded in 2009 and headquartered in San Francisco, California, develops therapies that control disease-causing proteins and develops drugs as treatments for hematologic cancers and immune-mediated diseases including immuno-oncology therapeutics for cancer.... Read More
